Within the framework of one of thevaccination campaign largest worldwide, the national government has already begun to apply two of the vaccines that demonstrated efficacy against coronavirus.
The Russian vaccine Sputnik V and the vaccine Covishield, produced in the India and developed by Oxford University and AstraZeneca, are the vaccines that have already begun to be applied in Argentina.
In addition, this Sunday the Minister of Health, Carla vizzotti, authorized the vaccine as an emergency SARS COV-2, developed by the Chinese pharmaceutical company Sinopharm in collaboration with the Beijing Institute of Biological Laboratory China Products.
The country begins this Monday the eighth week of the vaccination campaign against him coronavirus and to date it has been distributed 1,173,115 doses and they were reported as applied 391,975 of the first component and 241,662 of the second of the vaccine developed by the Gamaleya Research Center of Russia.
In January, National Administration of Medicines, Food and Medical Technology (ANMAT) approved the emergency use of the Oxford Aztrazeneca vaccinefor application in Argentina.
The week before they arrived in the country580 thousand doses of the vaccine Covishield, prepared at the Serum Institute of theIndia and developed by Oxford Y AstraZeneca, and the distribution of the doses in the provinces began.
This vaccine can be safely stored at temperatures from 2 ° C to 8 ° C, about the same as a domestic refrigerator.
Chinese vaccine: Sinopharm
The Minister of Health, Carla vizzotti, today signed resolution 688/2021 that authorizes the vaccine as an emergency SARS COV-2, developed by the Chinese pharmaceutical company Sinopharm in collaboration with the laboratory Beijing Institute of Biological Products of China, reported official sources.
The decision was signed by Vizzotti after the National Administration of Medicines, Food and Medical Technology (ANMAT) recommend to the Ministry of Health the incorporation of this vaccine in the immunization campaign carried out by the Government within the framework of Law 27,573 / 2020 (vaccines designed to generate acquired immunity against Covid-19), sanctioned at the end of October
One million doses of the coronavirus vaccine developed by the Chinese laboratory Sinopharm will arrive on Thursday from Beijing.
The million doses of Sinopharm will allow to immunize 500,000 people, since this drug, like most vaccines against Covid-19, requires two applications.
Sputnik V vaccine
The Sputnik V vaccine, developed by the Institute of Gamaleya Research from Russia, already reported 391,975 of the first component and 241,662 of the second of the vaccine as applied.
The arrival of a new batch of doses of the Sputnik V.
On February 2, the prestigious scientific journal The Lancet published the results of interim studies from phase 3 trials of the Sputnik V vaccine, developed by the Gamaleya Research Center of Russia, which showed an efficacy of 91.6 percent in the prevention of coronavirus.
The analysis included data from 19,866 volunteers who received both the first and the second dose of the vaccine. Lto Sputnik V it provided « complete protection against serious cases, » according to the publication.
Efficacy in the group 2,144 volunteers older than 60 years was 91.8 percent and did not differ statistically from the group of 18 to 60 years.
Furthermore, among the cases analyzed, more than 98 percent of the volunteers developed a humoral immune response and a 100 percent cellular immune response.